|
65675c59212eaade2e0cd4d0
|
2020
|
UNICEF
|
UNICEF
|
2020007102
|
1410/A0/06/002/003
|
8
|
Ethiopia
|
South of Sahara
|
LDCs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.098
|
0.098
|
0
|
0
|
0.098
|
0.098
|
|
|
|
|
Child health
|
Nutrition
|
100
|
003 SYSTEMS STRENGTHENING
|
003 SYSTEMS STRENGTHENING
|
003 SYSTEMS STRENGTHENING
|
|
12240
|
Basic nutrition
|
5,2
|
I.2.b. Basic Health
|
41122
|
United Nations Children's Fund
|
UNICEF
|
|
|
|
65675c59212eaade2e0cd4d1
|
2020
|
Germany
|
Foreign Office
|
2020008493
|
6612240
|
8
|
Syrian Arab Republic
|
Middle East
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
26.66666665
|
26.66666665
|
0
|
0
|
205.128205
|
205.128205
|
|
205.128205
|
|
0
|
Child health
|
Nutrition
|
13
|
FOOD EMERGENCY ASSISTANCE AND ...FOOD AID FOR CONFLICT-AFFECTED PEOPLE IN SYRIA
more
|
Food Emergency assistance and ...food aid for conflict-affected people in Syria
more
|
Food Emergency assistance and ...food aid for conflict-affected people in Syria
more
|
Mixed and blended food 128 974... 323. Total (food and cash-based transfer value) 964 605 741. (SYR 6612240 Food Emergency assistance and food aid for conflict-affected people in Syria p.22)
more
|
72040
|
Emergency food assistance
|
|
VIII.1. Emergency Response
|
41140
|
World Food Programme
|
World Food Programme (WFP)
|
|
|
|
65675c59212eaade2e0cd4d2
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007122
|
GCRF_MRC_ZAF_MR/T029803/1
|
3
|
South Africa
|
South of Sahara
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.46821
|
0
|
0
|
0
|
0.46821
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
AN INTER-DISCIPLINARY APPROACH... TO UNDERSTANDING AND INTERVENING ON CONTEXTUAL FACTORS THAT SHAPE HIV-RISK FOR YOUNG WOMEN AND MEN IN SOUTH AFRICA
more
|
An inter-disciplinary approach... to understanding and intervening on contextual factors that shape HIV-risk for young women and men in South Africa
more
|
Globally, and in South Africa ...in particular, HIV remains a major public health challenge. In KwaZulu-Natal Province, the functional epicentre of the global HIV-epidemic, young women and girls (18-24) are particularly at risk of acquiring HIV, and young men, are the only group in the country with an rising HIV-incidence. These high rates of HIV-acquisition are driven by harsh social contexts of poverty, inequitable gender norms, and widespread levels of violence, driven by the long legacy of apartheid. This project seems to achieve three aims: 1) to understand how social contexts shape young people's HIV-acquisition risk, 2) to develop an intervention to support young women and men to take control of their lives and HIV-acquisition risk, and 3) assess the feasibility, acceptability and potential impact of this intervention. To achieve aim 1 we will use unique existing quantitative data sets to understand how social contexts shape HIV-acquisition risk in young people and then undertake long-term participatory research with 16 youth peer research associates (YPRAs) hired from two sites in KwaZulu-Natal - urban informal settlements and rural KwaZulu-Natal. Through this we will understand in multiple ways how risk manifests itself. To achieve aim 2 we will work with the YPRAs and the team of researchers to develop an intervention with resonates with young women's and men's live. To achieve aim 3 we will undertake a pilot evaluation of the intervention, assessing quantitative and qualitatively whether the intervention was felt to be feasible and acceptable by young people, and whether it shows any evidence of effect. We will share results with the community through producing plain language summaries of the research we produce, and also a short video at endline, all in collaboration with the YPRAs.
more
|
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65675c59212eaade2e0cd4d3
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007409
|
GCRF-RAECImFFF-1920-1-FF\1920\...1\23
more
|
3
|
South Africa
|
South of Sahara
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.220598
|
0
|
0
|
0
|
0.220598
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
FRONTIERS FOLLOW-ON FUNDING
|
Frontiers Follow-on Funding
|
This project led by researcher...s in the UK and South Africa is titled 'Optimised electronic patient records to improve clinical monitoring of HIV-positive patients in rural South Africa (MONART Trial)' the project is aimed at conducting a review of the viral load monitoring process within the health system to identify gaps, with a view to developing a quality improvement package (QIP) to address the gaps.
more
|
|
43082
|
Research/scientific institutio...ns
more
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65675c59212eaade2e0cd4d4
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007632
|
GCRF-RFChlG-R12018-CHL\R1\1801...42
more
|
3
|
South Africa
|
South of Sahara
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.25611
|
0
|
0
|
0
|
0.25611
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
DEVELOPING NOVEL THERAPEUTIC A...PPROACHES FOR KAPOSI'S SARCOMA, THE MOST COMMON HIV-ASSOCIATED CANCER IN SUB-SAHARAN AFRICA
more
|
Developing novel therapeutic a...pproaches for Kaposi's sarcoma, the most common HIV-associated cancer in Sub-Saharan Africa
more
|
Research Grant – interdiscip...linary consortium based in UK and South Africa developing specific antiviral reagents for Kaposi's sarcoma, the most common HIV-associated cancer in Sub-Saharan Africa. The project will improve the health of disadvantaged populations and the lives of individuals suffering from KSHV-associated diseases through novel drug discovery. SDGs 3,17.
more
|
|
12350
|
Other prevention and treatment... of NCDs
more
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65675c59212eaade2e0cd4d5
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007615
|
GCRF-RSRFFLAIR-FCGR120-FCG\R1\...201012
more
|
3
|
South Africa
|
South of Sahara
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.064127
|
0
|
0
|
0
|
0.064127
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
IMPACT OF HIV EXPOSURE ON INTR...AUTERINE IMMUNE EPIGENETICS: SEX-SPECIFIC AUTOSOMAL DNA METHYLATION CHANGES ARISING IN UTERO IN SEX-DISCORDANT
more
|
Impact of HIV exposure on intr...auterine immune epigenetics: Sex-specific autosomal DNA methylation changes arising in utero in sex-discordant
more
|
Research Grant - Collaboration... between UK and a FLAIR Fellow based in South Africa. Investigating the rates of DNA methylation in sex-discordant and same-sex twins in utero, to determine whether this affects HIV infection susceptibility. SDGs 3,10.
more
|
|
13040
|
STD control including HIV/AIDS
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65675c59212eaade2e0cd4d6
|
2020
|
UNICEF
|
UNICEF
|
2020007631
|
1620/A0/05/801/002
|
8
|
Ghana
|
South of Sahara
|
LMICs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.188
|
0.188
|
0
|
0
|
0.188
|
0.188
|
|
|
|
|
Communicable diseases
|
Communicable diseases Other
|
100
|
OUTPUT 2: QUALITY OF CARE
|
OUTPUT 2: QUALITY OF CARE
|
OUTPUT 2: QUALITY OF CARE
|
|
12250
|
Infectious disease control
|
5,3
|
I.2.b. Basic Health
|
41122
|
United Nations Children's Fund
|
UNICEF
|
|
|
|
65675c59212eaade2e0cd4d7
|
2020
|
UNICEF
|
UNICEF
|
2020007628
|
6110/A0/05/883/004
|
8
|
Belize
|
Caribbean & Central America
|
UMICs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.001
|
0.001
|
0
|
0
|
0.001
|
0.001
|
|
|
|
|
Sector-wide health programmes
|
Sector-wide health programmes ...Other
more
|
100
|
ORGANIZATIONAL CAPACITY-EDUCAT...ION
more
|
ORGANIZATIONAL CAPACITY-EDUCAT...ION
more
|
ORGANIZATIONAL CAPACITY-EDUCAT...ION
more
|
|
12261
|
Health education
|
6,5
|
I.2.b. Basic Health
|
41122
|
United Nations Children's Fund
|
UNICEF
|
0
|
|
|
65675c59212eaade2e0cd4d8
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007617
|
GCRF-RSRFFLAIR-FR12020-FLR\R1\...201494
more
|
3
|
South Africa
|
South of Sahara
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.146691
|
0
|
0
|
0
|
0.146691
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
CHARACTERISATION OF THE HIV-1 ...RESERVOIR AND REBOUND VIRUS IN BLOOD AND TISSUES
more
|
Characterisation of the HIV-1 ...reservoir and rebound virus in blood and tissues
more
|
Fellowship award based in Sout...h Africa. Investigating ongoing HIV replication during anti-retroviral therapy, to inform priorities for HIV cure (i.e. improving drug penetration into tissues or focussing on elimination of infected cells). SDG 3.
more
|
|
13040
|
STD control including HIV/AIDS
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65675c59212eaade2e0cd4d9
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007734
|
UKRI_NS_EP/T030429/1_DIDA
|
3
|
South Africa
|
South of Sahara
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.0831705
|
0
|
0
|
0
|
0.166341
|
0
|
0
|
0
|
0
|
Other health problems
|
Other health problems Research... and Development
more
|
50
|
CO-DESIGNING COMMUNITY-BASED I...CTS INTERVENTIONS TO ENHANCE MATERNAL AND CHILD HEALTH IN SOUTH AFRICA
more
|
Co-designing Community-based I...CTs Interventions to Enhance Maternal and Child Health in South Africa
more
|
Digital interventions to suppo...rt maternal and child health (MCH) are widespread. Yet, the impact of these interventions in low-income communities is limited. We believe this is in part due to the top-down nature of digital health development, and propose to take a participatory and community-centred approach to this domain. We will form a multidisciplinary, cross-cultural, and cross-geographical consortium of researchers, technology designers, healthcare professionals and community stakeholders, policy makers, and grassroots citizens' organizations to explore the potential of information and communication technologies (ICTs) to enhance maternal and child health and wellbeing during the antenatal and postnatal period in South Africa.
more
|
|
43082
|
Research/scientific institutio...ns
more
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65675c59212eaade2e0cd4da
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007127
|
GCRF_MRC_NS_MR/P014313/1
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.01186
|
0
|
0
|
0
|
0.01186
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
ASSESSING POLICY IMPLEMENTATIO...N AND HEALTH SYSTEMS IMPACTS OF OPTION B+ IN THREE AFRICAN COUNTRIES TO INFORM THE DELIVERY OF UNIVERSAL TEST AND TREAT.
more
|
Assessing policy implementatio...n and health systems impacts of Option B+ in three African countries to inform the delivery of Universal Test and Treat.
more
|
In 2013, the World Health Orga...nisation (WHO) recommended initiation of lifelong antiretroviral therapy (ART) for all HIV-positive pregnant women, regardless of disease stage, in order to minimise transmission risks to their index offspring and offspring of later pregnancies. HIV-exposed infants should receive antiretroviral (ARV) prophylaxis, be tested and receive ART if HIV-positive. In 2015, WHO extended their guidance to recommend immediate ART initiation for all adults diagnosed with HIV (universal Test and Treat (UTT)), following evidence from randomised control trials demonstrating that it reduced sexual transmission and provided individual health benefits for HIV-positive adults. Although few sub-Saharan African countries have introduced UTT policies, many have rolled out Option B+, despite ongoing debates over its cost-effectiveness and health systems impacts, particularly in settings with weak infrastructure. Despite its potential to eliminate HIV in infants and improve maternal health, some argue that poor delivery could lead to resources being channelled away from adult HIV services, detrimentally affecting their quality and health outcomes. There is widespread agreement that research is needed to understand how Option B+ has been implemented in different settings and its corresponding impacts on health systems. Furthermore, there is a key window of opportunity to use the evidence generated by such research to assess how best to prepare these health systems for further expansion of ART services as UTT policies are rolled out. Our study will take place in three HIV community cohort (HCC) sites in rural Malawi, Tanzania and South Africa, representing early, mid-term and late adopters of Option B+ in 2011, 2013 and 2015 respectively, and where UTT policies were being drafted in 2016, in order to answer 4 key research questions: 1) What are the Option B+ policy implementation gaps in each setting and how do the actors, policy content, context and processes explain these gaps? 2) Have underlying economic and epidemiological assumptions in economic evaluations that demonstrated the anticipated cost-effectiveness of Option B+ been met in each site? 3) What are the health systems impacts of Option B+ in each setting? 4) What strategies can be developed with policymakers to ensure that health systems are ready for effective delivery of UTT? We will use a comparative, longitudinal approach with mixed methods that include secondary analysis of existing policy reviews, health facility survey data and routine HIV clinic data linked to HCC data. We will also collect new data through an updated review of national HIV policies, a further round of facility surveys, key informant interviews with policymakers and programmers, in-depth interviews with health workers and PMTCT service users, and costing estimates. We will draw on existing frameworks to identify gaps in Option B+ implementation and to explore the policy processes and contexts unde
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65675c59212eaade2e0cd4db
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007131
|
GCRF_MRC_NS_MR/P022251/1
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.081488
|
0
|
0
|
0
|
0.081488
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MECHANISMS UNDERLYING ENHANCED... INFECTION PROPHYLAXIS FOR ADVANCED HIV IN AFRICA
more
|
Mechanisms underlying enhanced... infection prophylaxis for advanced HIV in Africa
more
|
Around one-quarter of people w...ith HIV in Africa have very advanced disease when they start treatment, and one-in-ten die during the first few months of taking HIV medicines. Deaths occur due to a variety of different infections and from a failing immune system, which is over-active but not efficient at fighting infections (so-called 'immune activation'). In the REALITY clinical trial, which enrolled 1805 children and adults in four African countries, we showed that giving these patients a 'bundle' of 5 different types of anti-infection medicines during the first 3 months of HIV treatment led to a 27% reduction in deaths. This new approach could save 3 lives for every 100 people treated with these extra anti-infection medicines, and has the advantage of being easy to deliver at community-based health clinics in Africa. Before scaling up this new intervention to reach more people with advanced HIV, decision-makers (such as the World Health Organization and National Ministries of Health) need to understand the pros and cons of such an approach. To help inform this process, we now need to understand exactly how this bundle of anti-infection medicines works. In the REALITY study, the 'bundle' reduced tuberculosis and fungal infections, but did not seem to have an effect on the number of worm or bacterial infections that were reported during the study. It is possible, therefore, that we do not need to include the 2 antibiotics (albendazole and azithromycin) that were meant to prevent worm and bacterial infections. If these two medicines are not needed in the 'bundle' this would save costs and reduce the risks of both side effects and developing antibiotic resistance. On the other hand, we may have missed diagnosing bacterial and worm infections in patients who died, because there are few facilities that can test for these infections in Africa and some patients died at home. This study will use blood and stool samples collected from patients who died or survived in the REALITY trial to try and understand how the bundle of anti-infection medicines worked. We will look at using more sensitive methods for detecting these bacteria and worms (by identifying their genetic material in patient samples) to see if azithromycin and albendazole helped to prevent infections in the bloodstream or gut. We will also look to see if these anti-infection medicines helped to reduce the high levels of unhealthy immune activation, which may stop people dying by preventing the immune system from getting exhausted and failing completely. If we find evidence that albendazole and azithromycin are important in reducing deaths, then they clearly need to be included in the bundle of anti-infection medicines. If we find no evidence that they contributed to reducing deaths, then they could be removed from the 'bundle'. Finally, even with this new bundle of care, 11% of patients with advanced HIV died by the end of the first year of HIV treatment, and we clearly need new ways of re
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65675c5a212eaade2e0cd4dc
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007643
|
GCRF-RSRFFLAIR-FR12020-FLR\R1\...201448
more
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.153977
|
0
|
0
|
0
|
0.153977
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
EFFECT OF LONG-TERM AZITHROMYC...IN TREATMENT ON THE RESPIRATORY MICROBIOTA OF HIV-INFECTED CHILDREN WITH CHRONIC LUNG DISEASE
more
|
Effect of long-term azithromyc...in treatment on the respiratory microbiota of HIV-infected children with chronic lung disease
more
|
Fellowship award based in Sout...h Africa. Investigating the effect of long-term azithromycin therapy on respiratory microbiota and the associated antibiotic resistance profile in HIV-infected children with and without chronic lung disease. SDG 3.
more
|
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65675c5a212eaade2e0cd4dd
|
2020
|
Germany
|
Foreign Office
|
2020009622
|
6615089
|
8
|
Eswatini
|
South of Sahara
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.017424
|
0.017424
|
0
|
0
|
0.017424
|
0.017424
|
|
0.017424
|
|
0
|
Classified as not health-speci...fic activity
more
|
|
100
|
ESWATINI MBABANE URBAN GARDENS
|
Eswatini Mbabane Urban Gardens
|
Construction of an allotment g...arden as expansion of an already existing Urban Gardens-project in Mbabane and construction of 15 satellite gardens in and around Mbabane. People shall be trained to plant and grow their own fruit and vegetables in a sustainable way. The aim is food security and climate adaption.
more
|
|
12240
|
Basic nutrition
|
|
I.2.b. Basic Health
|
23000
|
Developing country-based NGO
|
Developing country-based NGO
|
|
|
|
65675c5a212eaade2e0cd4de
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007165
|
GCRF_MRC_UGA_MR/P008852/1
|
3
|
Uganda
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.750968
|
0
|
0
|
0
|
0.750968
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
THE IMMUNOLOGICAL BASIS OF SUS...CEPTIBILITY TO NONTYPHOIDAL SALMONELLA BACTERAEMIA AMONG HIV-INFECTED ADULTS IN UGANDA
more
|
The immunological basis of sus...ceptibility to nontyphoidal Salmonella bacteraemia among HIV-infected adults in Uganda
more
|
Nontyphoidal strains of Salmon...ella are a major cause of fatal bloodstream infection in Africa, particularly among young children and people living with HIV/AIDS. These Salmonella infections are difficult to diagnose and antibiotic resistance is an increasing problem, so an effective vaccine against nontyphoidal Salmonella (NTS) has the potential to save many lives. Vaccines currently in development against NTS aim to work by stimulating the production of antibodies to a sugar known as O-antigen which is part of the lipopolysaccharide (LPS) molecule and found on the Salmonella surface. My previous research has shown that some HIV-infected adults in Africa have very high levels of these antibodies which then block killing of the Salmonella bacteria. Hence there is a risk that these vaccines may cause harm to people with HIV. This project aims to understand the basis for susceptibility to NTS bloodstream infections in HIV-infected Africans, and in particular to understand the phenomenon of blocking antibodies, with a view to designing improved vaccines that will protect HIV-infected groups against NTS. I hypothesise that NTS is present at increased levels in the gut in HIV infection and that because the gut wall does not function properly in these patients, the Salmonella bacteria are able to invade the bloodstream. Here they can go on to cause severe disease and death due to the inability of the immune system to kill these bacteria, because of the presence of blocking levels of antibodies. I hypothesise that the continual movement of Salmonella and Salmonella LPS into the circulation drives the production of these high levels of blocking antibodies, because antibody production is no longer appropriately regulated in HIV infection. I will test this hypothesis in a group of adults newly-diagnosed with HIV infection in Uganda, studying them for two years after they commence antiretroviral therapy (ART) and comparing them with HIV-uninfected subjects. Incidence of NTS bloodstream infections initially rises when starting ART and then falls, but remains much higher than in HIV-uninfected subjects. Therefore, looking at specific immune parameters with time on ART will help understand which are most relevant to susceptibility to NTS infection. Since compromise of the barrier state of the gut is key to my hypothesis, I will study samples of gut tissue taken at endoscopy, as well as peripheral blood. First, I will test to see whether NTS is present in the gut of HIV-infected participants and whether it occurs more frequently and at higher levels than in HIV-uninfected controls. Then I will investigate the transfer of Salmonella from the gut to the bloodstream and compare this with the immune status of the gut wall, seeing whether this transfer is associated with loss of particular groups of immune cells known as Th17 and mucosal-associated invariant T (MAIT) cells. Finally, I will study the levels and function of antibodies targeting LPS O-antigen, to det
more
|
0
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65675c5a212eaade2e0cd4df
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008522
|
MRC_UGA_MR/R023182/1
|
3
|
Uganda
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.326868
|
0
|
0
|
0
|
0.326868
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
RISK FACTORS FOR GENITAL INFLA...MMATION AMONG WOMEN AT HIGH RISK OF HIV IN UGANDA: A MIXED-METHOD, LONGITUDINAL ANALYSIS
more
|
Risk factors for genital infla...mmation among women at high risk of HIV in Uganda: a mixed-method, longitudinal analysis
more
|
MRC PSMB award - Risk factors ...for genital inflammation among women at high risk of HIV in Uganda: a mixedmethod, longitudinal analysis
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65675c5a212eaade2e0cd4e0
|
2020
|
UNICEF
|
UNICEF
|
2020007163
|
4590/A0/05/882/002
|
8
|
Burkina Faso
|
South of Sahara
|
LDCs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.002
|
0.002
|
0
|
0
|
0.002
|
0.002
|
|
|
|
|
Child health
|
Nutrition
|
100
|
DESIGN SCALING UP PLANS OF NUT...RITION INTERVENTIONS
more
|
DESIGN SCALING UP PLANS OF NUT...RITION INTERVENTIONS
more
|
DESIGN SCALING UP PLANS OF NUT...RITION INTERVENTIONS
more
|
|
12110
|
Health policy and administrati...ve management
more
|
2
|
I.2.a. Health, General
|
41122
|
United Nations Children's Fund
|
UNICEF
|
|
|
|
65675c5a212eaade2e0cd4e1
|
2020
|
Germany
|
Foreign Office
|
2020008528
|
6613030
|
3
|
Lebanon
|
Middle East
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
1.823362
|
0
|
0
|
0
|
1.823362
|
|
0
|
|
0
|
Sector-wide health programmes
|
Health system strengthening (a...ll building blocks)
more
|
100
|
HEALTH CARE IN LEBANON
|
Health care in Lebanon
|
Mobile health care for conflic...t-affected Syrian refugees and the receiving Lebanese communities
more
|
0
|
72010
|
Material relief assistance and... services
more
|
|
VIII.1. Emergency Response
|
22000
|
Donor country-based NGO
|
Donor country-based NGO
|
|
|
|
65675c5a212eaade2e0cd4e2
|
2020
|
Switzerland
|
Swiss Agency for Development a...nd Co-operation
more
|
2020008525
|
7F-01352.13.37
|
3
|
Rwanda
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.023573
|
0
|
0
|
|
0.023573
|
|
|
|
|
Sector-wide health programmes
|
Sector-wide health programmes ...Other
more
|
100
|
STRONG FAMILY STRONG SOCIETY (...SFSS) - SMALL ACTION CREDIT
more
|
Strong Family Strong Society (...SFSS) - small action credit
more
|
Les crédits globaux pour peti...tes actions permettent le financement d'opérations ponctuelles, peu coûteuses, significatives en termes de développement, à composantes diverses (techniques, sociales, organisationnelles et de gestion, politique, économique, informative, etc.)
more
|
|
12261
|
Health education
|
3.b,16
|
I.2.b. Basic Health
|
12001
|
Central Government
|
|
|
|
|
65675c5a212eaade2e0cd4e3
|
2020
|
UNICEF
|
UNICEF
|
2020007168
|
3210/A0/06/001/001
|
8
|
Nigeria
|
South of Sahara
|
LMICs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.083
|
0.083
|
0
|
0
|
0.083
|
0.083
|
|
|
|
|
Projects of reproductive healt...h
more
|
Reproductive Health General
|
100
|
1.1 MNCH SYSTEMS
|
1.1 MNCH SYSTEMS
|
1.1 MNCH SYSTEMS
|
|
13020
|
Reproductive health care
|
3
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
41122
|
United Nations Children's Fund
|
UNICEF
|
|
|
|
65675c5a212eaade2e0cd4e4
|
2020
|
Germany
|
Foreign Office
|
2020008530
|
6613033
|
3
|
Sudan
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.1751277
|
0
|
0
|
0
|
0.265345
|
|
0
|
|
0
|
Sector-wide health programmes
|
Health system strengthening (a...ll building blocks)
more
|
66
|
LIFE-SAVING HYGIENE MEASURES, ...HEALTH AND NUTRITION AID FOR INTERNALLY DISPLACED PEOPLE AND HOST COMMUNITIES IN SOUTH KORDOFAN
more
|
Life-saving hygiene measures, ...health and nutrition aid for internally displaced people and host communities in South Kordofan
more
|
Life-saving hygiene measures, ...health and nutrition aid for internally displaced people and host communities in South Kordofan
more
|
0
|
72010
|
Material relief assistance and... services
more
|
|
VIII.1. Emergency Response
|
22000
|
Donor country-based NGO
|
Donor country-based NGO
|
|
|
|
65675c5a212eaade2e0cd4e5
|
2014
|
United States
|
HHS
|
2014026302
|
35_32
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
375.83
|
187.915
|
0
|
0
|
375.83
|
187.915
|
0
|
375.83
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
NATIONAL INSTITUTE OF HEALTH -... INTERNATIONAL RESEARCH
more
|
National Institute of Health -... International Research
more
|
PEPFAR - The President s Emerg...ency Plan for AIDS Relief is committed to prevent new HIV infections; treat HIV-infected individuals and those orphaned by AIDs.
more
|
The intent of this FOA is to s...olicit implementation science research projects that will have a high impact on controlling the HIV epidemic and provide evidence for best programmatic practices in PEPFAR programs. A more complete description of programmatic priorities for PEPFAR, as well as a rationale for the pivot to a data-driven approach that strategically targets resources towards geographic areas and populations where the greatest impact in epidemic control is most likely to occur, can be found at: http://www.pepfar.gov/documents/organization/234744.pdf.
Studies submitted in response to this FOA should address the challenges that PEPFAR encounters in the implementation of HIV/AIDS prevention, treatment, and care programs for antenatal, pediatric, adolescent, and adult populations (including pregnant and breastfeeding women) in eligible African countries. Within the countries of focus for this FOA, the expectation is that research will be conducted in regions most affected by HIV/AIDS (high prevalence, high incidence settings) among neglected and hard-to-reach populations with low service coverage and a potential for high impact, such as pediatric populations, adolescent girls and young women, high-risk men, and sex workers. Priorities should reflect those of the country and also produce results that are generalizable across PEPFAR programs. Studies that use existing clinical, administrative, or programmatic data to study resource allocation and how to maximize impact are particularly important.
more
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
11000
|
Donor government
|
Donor Government
|
|
|
|
65675c5a212eaade2e0cd4e6
|
2014
|
UNFPA
|
UNFPA
|
2014000599
|
|
1
|
Cambodia
|
Far East Asia
|
LDCs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.0045
|
0.0045
|
0
|
0
|
0.0045
|
0.0045
|
|
|
|
|
Classified as not health-speci...fic activity
more
|
|
100
|
ANALYSIS ON POPULATION DYNAMIC...S
more
|
Output 13: Analysis on populat...ion dynamics
more
|
Cambodia - Phnom-Penh - Outcom...e 4: Strengthened national policies and international development agendas through integration of evidence-based analysis on population dynamics
more
|
Analysis on population dynami...cs
more
|
13010
|
Population policy and administ...rative management
more
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
|
|
|
|
|
|
65675c5a212eaade2e0cd4e7
|
2014
|
United States
|
AID
|
2014028909
|
76_45735
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
11.937
|
1.43037
|
0
|
0
|
11.937
|
1.43037
|
0
|
11.937
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
COMPLETION OF PHASE III MICROB...ICIDE CLINICAL TRIAL FOR TENOFOVIR 1% GEL - HIV/AIDS
more
|
Completion of Phase III Microb...icide Clinical Trial for Tenofovir 1% Gel - HIV/AIDS
more
|
The objectives of this program... are to complete clinical and regulatory activities required for licensure of tenofovir (TFV) 1% gel for the prevention of vaginal HIV acquisition in women and to provide information about its implementation in African populations. This project includes the following activities: 1) Completing clinical activities required for TFV 1% gel licensure; 2) Completing regulatory activities required for TFV 1% gel licensure; 3) Conducting open-label TFV 1% gel Implementation Studies in South Africa and other African countries; 4) Conducting a bridging study for the approval of one TFV 1% gel that is safe and acceptable for vaginal and rectal use.
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65675c5a212eaade2e0cd4e8
|
2014
|
United States
|
AID
|
2014028908
|
76_45735
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.2
|
0
|
0
|
0
|
0.2
|
0
|
0
|
0.2
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
COMPLETION OF PHASE III MICROB...ICIDE CLINICAL TRIAL FOR TENOFOVIR 1% GEL - PRIVATE SECTOR CAPACITY
more
|
Completion of Phase III Microb...icide Clinical Trial for Tenofovir 1% Gel - Private Sector Capacity
more
|
The objectives of this program... are to complete clinical and regulatory activities required for licensure of tenofovir (TFV) 1% gel for the prevention of vaginal HIV acquisition in women and to provide information about its implementation in African populations. This project includes the following activities: 1) Completing clinical activities required for TFV 1% gel licensure; 2) Completing regulatory activities required for TFV 1% gel licensure; 3) Conducting open-label TFV 1% gel Implementation Studies in South Africa and other African countries; 4) Conducting a bridging study for the approval of one TFV 1% gel that is safe and acceptable for vaginal and rectal use.
more
|
|
25010
|
Business support services & in...stitutions
more
|
|
II.5. Business & Other Service...s
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65675c5a212eaade2e0cd4e9
|
2014
|
United States
|
AID
|
2014029130
|
76_45887
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.25
|
0.16409
|
0
|
0
|
0.25
|
0.16409
|
0
|
0.25
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
DUAL RING - HIV/AIDS
|
Dual Ring - HIV/AIDS
|
Multipurpose Prevention Techno...logies (MPTs)--Biomed Research for RH, APS, Dual Vaginal (DPV+LNG) Rings.
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
30006
|
International Partnership on M...icrobicides
more
|
International Partnership on M...icrobicides
more
|
|
|
|
65675c5a212eaade2e0cd4ea
|
2014
|
United States
|
AID
|
2014029586
|
76_46199
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.40025
|
0
|
0
|
0
|
0.40025
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
HEALTH RESEARCH CHALLENGE FOR ...IMPACT - HIV/AIDS
more
|
Health Research challenge for ...Impact - HIV/AIDS
more
|
The aim of Health Research Cha...llenge for Impact (HRCI) is to accelerate the development and introduction of new, feasible, culturally acceptable, low-cost, preventive and curative interventions for the main causes of maternal, newborn and child deaths.
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65675c5a212eaade2e0cd4eb
|
2014
|
United States
|
AID
|
2014030001
|
76_46612
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.34198
|
0.30843
|
0
|
0
|
0.34198
|
0.30843
|
0
|
0.34198
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MICROBICIDE RESEARCH, DEVELOPM...ENT, AND INTRODUCTION, ROUND 2 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 2 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 2
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
22000
|
National NGOs
|
FHI 360
|
|
|
|
65675c5a212eaade2e0cd4ec
|
2014
|
United States
|
AID
|
2014030004
|
76_46615
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
1.18715
|
0.37721
|
0
|
0
|
1.18715
|
0.37721
|
0
|
1.18715
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MICROBICIDE RESEARCH, DEVELOPM...ENT, AND INTRODUCTION, ROUND 2 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 2 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 2
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65675c5a212eaade2e0cd4ed
|
2014
|
United States
|
AID
|
2014030008
|
76_46617
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.477
|
0.11915
|
0
|
0
|
0.477
|
0.11915
|
0
|
0.477
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MICROBICIDE RESEARCH, DEVELOPM...ENT, AND INTRODUCTION, ROUND 2 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 2 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 2
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65675c5a212eaade2e0cd4ee
|
2014
|
United States
|
AID
|
2014030009
|
76_46618
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.17651
|
0.19373
|
0
|
0
|
0.17651
|
0.19373
|
0
|
0.17651
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MICROBICIDES RESEARCH, DEVELOP...MENT, AND INTRODUCTION - HIV/AIDS
more
|
Microbicides Research, Develop...ment, and Introduction - HIV/AIDS
more
|
Microbicides Research, Develop...ment, and Introduction
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
22000
|
National NGOs
|
AIDS Vaccine Advocacy Coalitio...n
more
|
|
|
|
65675c5a212eaade2e0cd4ef
|
2014
|
United States
|
AID
|
2014030010
|
76_46619
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.09218
|
0.05906
|
0
|
0
|
0.09218
|
0.05906
|
0
|
0.09218
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MICROBICIDES RESEARCH, DEVELOP...MENT, AND INTRODUCTION - HIV/AIDS
more
|
Microbicides Research, Develop...ment, and Introduction - HIV/AIDS
more
|
Microbicides Research, Develop...ment, and Introduction
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
22000
|
National NGOs
|
AIDS Vaccine Advocacy Coalitio...n
more
|
|
|
|
65675c5a212eaade2e0cd4f0
|
2014
|
United States
|
AID
|
2014030011
|
76_46620
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.43659
|
0.40104
|
0
|
0
|
0.43659
|
0.40104
|
0
|
0.43659
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MICROBICIDES RESEARCH, DEVELOP...MENT, AND INTRODUCTION - HIV/AIDS
more
|
Microbicides Research, Develop...ment, and Introduction - HIV/AIDS
more
|
Microbicides Research, Develop...ment, and Introduction
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
22000
|
National NGOs
|
AIDS Vaccine Advocacy Coalitio...n
more
|
|
|
|
65675c5a212eaade2e0cd4f1
|
2014
|
United States
|
AID
|
2014028907
|
76_45735
|
1
|
South Africa
|
South of Sahara
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
1.5
|
1.5
|
0
|
0
|
1.5
|
1.5
|
0
|
1.5
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
COMPLETION OF PHASE III MICROB...ICIDE CLINICAL TRIAL FOR TENOFOVIR 1% GEL - HIV/AIDS
more
|
Completion of Phase III Microb...icide Clinical Trial for Tenofovir 1% Gel - HIV/AIDS
more
|
The objectives of this program... are to complete clinical and regulatory activities required for licensure of tenofovir (TFV) 1% gel for the prevention of vaginal HIV acquisition in women and to provide information about its implementation in African populations. This project includes the following activities: 1) Completing clinical activities required for TFV 1% gel licensure; 2) Completing regulatory activities required for TFV 1% gel licensure; 3) Conducting open-label TFV 1% gel Implementation Studies in South Africa and other African countries; 4) Conducting a bridging study for the approval of one TFV 1% gel that is safe and acceptable for vaginal and rectal use.
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65675c5a212eaade2e0cd4f2
|
2014
|
United States
|
AID
|
2014029581
|
76_46199
|
1
|
Tanzania
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.60247
|
0.19712
|
0
|
0
|
0.60247
|
0.19712
|
0
|
0.60247
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
HEALTH RESEARCH CHALLENGE FOR ...IMPACT - HIV/AIDS
more
|
Health Research challenge for ...Impact - HIV/AIDS
more
|
The aim of Health Research Cha...llenge for Impact (HRCI) is to accelerate the development and introduction of new, feasible, culturally acceptable, low-cost, preventive and curative interventions for the main causes of maternal, newborn and child deaths.
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65675c5a212eaade2e0cd4f3
|
2014
|
African Development Fund
|
AfDF
|
2014000602
|
2100150000000
|
3
|
Guinea
|
South of Sahara
|
LDCs
|
ODA Loans
|
4
|
10
|
410
|
C01
|
0
|
0
|
0.04516
|
0
|
0
|
0
|
0.04516
|
0
|
0
|
0
|
Classified as not health-speci...fic activity
more
|
|
100
|
NERICA DISSEMINATION PROJECT -... GUINEA
more
|
NERICA DISSEMINATION PROJECT -... GUINEA
more
|
AfDB Sector: Agriculture and R...ural Development. AfDB Sub-sector: Agriculture.
more
|
|
31110
|
Agricultural policy & administ...rative management
more
|
|
III.1.a. Agriculture
|
12000
|
Recipient government
|
|
|
|
|
65675c5a212eaade2e0cd4f4
|
2015
|
UNICEF
|
UNICEF
|
2015001553
|
8970/A0/05/001/003
|
8
|
Serbia
|
Europe
|
UMICs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.00495526
|
0.00495526
|
0
|
0
|
0.00495526
|
0.00495526
|
0
|
10
|
1
|
12
|
Classified as not health-speci...fic activity
more
|
|
100
|
SUPPORTING SOCIAL WELFARE SYST...EM REFORM
more
|
SUPPORTING SOCIAL WELFARE SYST...EM REFORM
more
|
SUPPORTING SOCIAL WELFARE SYST...EM REFORM
more
|
|
15160
|
Human rights
|
|
I.5.a. Government & Civil Soci...ety-general
more
|
|
|
|
|
|
|
65675c5a212eaade2e0cd4f5
|
2015
|
United States
|
AID
|
2015009537cex
|
76_39198
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.075095
|
0
|
0
|
0
|
0.075095
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
HEALTH RESEARCH CHALLENGE FOR ...IMPACT - HIV/AIDS
more
|
Health Research challenge for ...Impact - HIV/AIDS
more
|
The aim of Health Research Cha...llenge for Impact (HRCI) is to accelerate the development and introduction of new, feasible, culturally acceptable, low-cost, preventive and curative interventions for the main causes of maternal, newborn and child deaths.
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think-tank
more
|
|
|
|
65675c5a212eaade2e0cd4f6
|
2015
|
United States
|
AID
|
2015010642
|
76_42389
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.1
|
0.435914
|
0
|
0
|
0.1
|
0.435914
|
0
|
0.1
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
DUAL RING - HIV/AIDS
|
Dual Ring - HIV/AIDS
|
Multipurpose Prevention Techno...logies (MPTs)--Biomed Research for RH, APS, Dual Vaginal (DPV+LNG) Rings.
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
30006
|
International Partnership on M...icrobicides
more
|
International Partnership on M...icrobicides
more
|
|
|
|
65675c5a212eaade2e0cd4f7
|
2015
|
United States
|
AID
|
2015012691
|
76_46421
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.491615
|
0.561643
|
0
|
0
|
0.491615
|
0.561643
|
0
|
0.491615
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MICROBICIDE RESEARCH, DEVELOPM...ENT, AND INTRODUCTION, ROUND 2 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 2 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 2
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
22000
|
National NGOs
|
FHI 360
|
|
|
|
65675c5a212eaade2e0cd4f8
|
2015
|
United States
|
AID
|
2015012694
|
76_46424
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
1.95673
|
0.974345
|
0
|
0
|
1.95673
|
0.974345
|
0
|
1.95673
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MICROBICIDE RESEARCH, DEVELOPM...ENT, AND INTRODUCTION, ROUND 2 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 2 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 2
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think-tank
more
|
|
|
|
65675c5a212eaade2e0cd4f9
|
2015
|
United States
|
AID
|
2015012697
|
76_46426
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.689
|
0.687962
|
0
|
0
|
0.689
|
0.687962
|
0
|
0.689
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MICROBICIDE RESEARCH, DEVELOPM...ENT, AND INTRODUCTION, ROUND 2 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 2 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 2
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think-tank
more
|
|
|
|
65675c5a212eaade2e0cd4fa
|
2015
|
United States
|
AID
|
2015012698
|
76_46427
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.085596
|
0.145116
|
0
|
0
|
0.085596
|
0.145116
|
0
|
0.085596
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MICROBICIDES RESEARCH, DEVELOP...MENT, AND INTRODUCTION - HIV/AIDS
more
|
Microbicides Research, Develop...ment, and Introduction - HIV/AIDS
more
|
Microbicides Research, Develop...ment, and Introduction
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
22000
|
National NGOs
|
AIDS Vaccine Advocacy Coalitio...n
more
|
|
|
|
65675c5a212eaade2e0cd4fb
|
2015
|
United States
|
AID
|
2015012699
|
76_46428
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.082138
|
0.059161
|
0
|
0
|
0.082138
|
0.059161
|
0
|
0.082138
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MICROBICIDES RESEARCH, DEVELOP...MENT, AND INTRODUCTION - HIV/AIDS
more
|
Microbicides Research, Develop...ment, and Introduction - HIV/AIDS
more
|
Microbicides Research, Develop...ment, and Introduction
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
22000
|
National NGOs
|
AIDS Vaccine Advocacy Coalitio...n
more
|
|
|
|
65675c5a212eaade2e0cd4fc
|
2015
|
United States
|
AID
|
2015012700
|
76_46429
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.466051
|
0
|
0
|
0
|
0.466051
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MICROBICIDES RESEARCH, DEVELOP...MENT, AND INTRODUCTION - HIV/AIDS
more
|
Microbicides Research, Develop...ment, and Introduction - HIV/AIDS
more
|
Microbicides Research, Develop...ment, and Introduction
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
22000
|
National NGOs
|
AIDS Vaccine Advocacy Coalitio...n
more
|
|
|
|
65675c5a212eaade2e0cd4fd
|
2015
|
United States
|
AID
|
2015013442
|
76_47397
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
8.94309
|
0
|
0
|
0
|
8.94309
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
COMPLETION OF PHASE III MICROB...ICIDE CLINICAL TRIAL FOR TENOFOVIR 1% GEL - HIV/AIDS
more
|
Completion of Phase III Microb...icide Clinical Trial for Tenofovir 1% Gel - HIV/AIDS
more
|
The objectives of this program... are to complete clinical and regulatory activities required for licensure of tenofovir (TFV) 1% gel for the prevention of vaginal HIV acquisition in women and to provide information about its implementation in African populations. This project includes the following activities: 1) Completing clinical activities required for TFV 1% gel licensure; 2) Completing regulatory activities required for TFV 1% gel licensure; 3) Conducting open-label TFV 1% gel Implementation Studies in South Africa and other African countries; 4) Conducting a bridging study for the approval of one TFV 1% gel that is safe and acceptable for vaginal and rectal use.
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think-tank
more
|
|
|
|
65675c5a212eaade2e0cd4fe
|
2015
|
United States
|
AID
|
2015013443
|
76_47397
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.2
|
0
|
0
|
0
|
0.2
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
COMPLETION OF PHASE III MICROB...ICIDE CLINICAL TRIAL FOR TENOFOVIR 1% GEL - PRIVATE SECTOR CAPACITY
more
|
Completion of Phase III Microb...icide Clinical Trial for Tenofovir 1% Gel - Private Sector Capacity
more
|
The objectives of this program... are to complete clinical and regulatory activities required for licensure of tenofovir (TFV) 1% gel for the prevention of vaginal HIV acquisition in women and to provide information about its implementation in African populations. This project includes the following activities: 1) Completing clinical activities required for TFV 1% gel licensure; 2) Completing regulatory activities required for TFV 1% gel licensure; 3) Conducting open-label TFV 1% gel Implementation Studies in South Africa and other African countries; 4) Conducting a bridging study for the approval of one TFV 1% gel that is safe and acceptable for vaginal and rectal use.
more
|
|
25010
|
Business support services & in...stitutions
more
|
|
II.5. Business & Other Service...s
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think-tank
more
|
|
|
|
65675c5a212eaade2e0cd4ff
|
2015
|
United States
|
AID
|
2015015060mxi
|
76_49013
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
10.4546
|
1.572
|
0
|
0
|
10.4546
|
1.572
|
0
|
10.4546
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
SUPPORTING OPERATIONAL AIDS RE...SEARCH (PROJECT SOAR) - HIV/AIDS
more
|
Supporting Operational AIDS Re...search (Project SOAR) - HIV/AIDS
more
|
Project SOAR uses the best ava...ilable science, research expertise, and state-of-the-art methodologies to generate critical evidence to improve HIV prevention, care, and treatment policies and programs around the world. Through Project SOAR, the Council and partners are conducting HIV and AIDS operations research around the world to identify practical solutions to improve HIV prevention, care, and treatment services. This collaborative five-year program helps strengthen the skills of local research institutions and individuals to conduct and use high-quality research to improve programs and policies, and ensure more efficient and effective delivery of critical services.
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
21000
|
International NGOs
|
Population Council
|
|
|
|
65675c5a212eaade2e0cd500
|
2015
|
United States
|
AID
|
2015016415
|
76_50159
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
1.99259
|
0.523622
|
0
|
0
|
1.99259
|
0.523622
|
0
|
1.99259
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MICROBICIDE RESEARCH, DEVELOPM...ENT, AND INTRODUCTION, ROUND 3 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 3 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 3
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
22000
|
National NGOs
|
FHI 360
|
|
|
|
65675c5a212eaade2e0cd501
|
2015
|
United States
|
AID
|
2015016416
|
76_50160
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.749877
|
0.066189
|
0
|
0
|
0.749877
|
0.066189
|
0
|
0.749877
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MICROBICIDE RESEARCH, DEVELOPM...ENT, AND INTRODUCTION, ROUND 3 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 3 - HIV/AIDS
more
|
Microbicide Research, Developm...ent, and Introduction, Round 3
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think-tank
more
|
|
|
